Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot proteomic analysis of clopidogrel in type 2 diabetes mellitus with stable coronary artery disease
2006-002292-40Phase 3Active
- Sponsor
- Fundación Investigación y Desarrollo en el Área Cardiovascular
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of clopidogrel in type 2 diabetes mellitus (T2DM) and coronary arteriosclerosis (2 arms), sponsored by Fundación Investigación y Desarrollo en el Área Cardiovascular. Primary endpoint: Change in expression of proteins associated with platelet activation. Started Jun 2006; status: active.
02
Drugs
clopidogrel
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosis
Beyond the preview
Go deeper on 2006-002292-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002292-40.